Table 1.
A shortlist of Chinese pharmaceutical and biopharmaceutical companies
| Company name | Type | STN | Sales 2019 (million CN¥; million €) |
R&D 2019 (million CN¥; million €) |
Biopharmaceutical products (examples) |
|---|---|---|---|---|---|
|
Jiangsu Hengruia 恒瑞医药 |
P | SHA:600276 | 23,289; 3015 | 3896; 504 | PD-1 monoclonal antibodies |
|
Shanghai Fosun Pharmab 上海复星医药 |
P | SHA: 600196 | 28,585; 3701 | 3463; 448 | Rituximab, H1N1 vaccine |
|
Qilu Pharmaceuticalc 齐鲁制药 |
S | – | 25,100; 3250 | 1600; 207 | Bevacizumab monoclonal antibody |
|
Zhejiang Hisund 海正药业 |
P | SHA: 600267 | 11,072; 1433 | 814; 105 | Insulin, adalimumab |
|
Chongqing Zhifeie 重庆智飞生物 |
P | SHE:300122 | 10,600; 1327 | 259; 34 | Hib vaccine, HPV vaccine, 23-valent pneumococcal polysaccharide vaccine, etc. |
|
Salubris Pharmaceuticalsf 信立泰药业 |
P | SHE: 002294 | 4,470; 579 | 763; 99 | Recombinant human parathyroid hormone |
|
Walvax Biotechnologyg 云南沃森生物技术 |
P | SHE: 300142 | 1121; 145 | 65; 8.4 | 23-Valent pneumococcal polysaccharide vaccine, etc. |
|
InnoventBioh 信达生物 |
P | HKG:1801 | 1048; 140 | 1294; 168 | PD-1 monoclonal antibody, 20 biomedical drugs in approval procedure or preclinical studies |
S state-owned company, P private company, STN stock trading number